Literature DB >> 8034210

Topical timolol with and without benzalkonium chloride: epithelial permeability and autofluorescence of the cornea in glaucoma.

C de Jong1, T Stolwijk, E Kuppens, R de Keizer, J van Best.   

Abstract

Epithelial permeability and autofluorescence of the cornea were determined by fluorophotometry in 21 patients with open-angle glaucoma or ocular hypertension using timolol medication with the preservative benzalkonium chloride (BAC) and 2 weeks after changing to timolol medication without BAC. The investigation was performed to determine whether removal of BAC would reduce toxic effects on the cornea and complaints of sensations of burning or dry eye. Corneal epithelial permeability decreased significantly after changing medication (mean decrease per patient 27%, P = 0.025). Corneal autofluorescence increased significantly after changing medication suggesting an alteration in corneal metabolism (mean increase per patient 6%, P = 0.003). Timolol without BAC was found to be as effective as timolol with BAC in reducing intraocular pressure (P = 0.4). Removal of BAC from timolol resulted in an improvement of corneal epithelial barrier function and in a reduction of complaints. The improvement was found to be proportional to the duration of the preceding BAC-containing therapy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8034210     DOI: 10.1007/bf00184009

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  12 in total

1.  Intrinsic fluorescence emission from the cornea at low temperatures: evidence of mitochondrial signals and their differing redox states in epithelial and endothelial sides.

Authors:  B Chance; M Lieberman
Journal:  Exp Eye Res       Date:  1978-01       Impact factor: 3.467

2.  Timolol and facility of outflow.

Authors:  T J Zimmerman; R Harbin; M Pett; H E Kaufman
Journal:  Invest Ophthalmol Vis Sci       Date:  1977-07       Impact factor: 4.799

3.  Corneal epithelial permeability after instillation of ophthalmic solutions containing local anaesthetics and preservatives.

Authors:  J A Ramselaar; J P Boot; N J van Haeringen; J A van Best; J A Oosterhuis
Journal:  Curr Eye Res       Date:  1988-09       Impact factor: 2.424

4.  Corneal autofluorescence in diabetic and penetrating keratoplasty patients as measured by fluorophotometry.

Authors:  T R Stolwijk; J A van Best; J P Boot; J A Oosterhuis
Journal:  Exp Eye Res       Date:  1990-10       Impact factor: 3.467

5.  Side effects of timolol.

Authors:  T J Zimmerman; J D Baumann; J Hetherington
Journal:  Surv Ophthalmol       Date:  1983-12       Impact factor: 6.048

6.  Noninvasive redox fluorometry: how light can be used to monitor alterations of corneal mitochondrial function.

Authors:  B R Masters
Journal:  Curr Eye Res       Date:  1984-01       Impact factor: 2.424

7.  The mechanism of timolol in lowering intraocular pressure. In the normal eye.

Authors:  R L Coakes; R F Brubaker
Journal:  Arch Ophthalmol       Date:  1978-11

8.  A simple method for determination of corneal epithelial permeability in humans.

Authors:  E J de Kruijf; J P Boot; L Laterveer; J A van Best; J A Ramselaar; J A Oosterhuis
Journal:  Curr Eye Res       Date:  1987-11       Impact factor: 2.424

9.  Corneal autofluorescence: an indicator of diabetic retinopathy.

Authors:  T R Stolwijk; J A van Best; J A Oosterhuis; W Swart
Journal:  Invest Ophthalmol Vis Sci       Date:  1992-01       Impact factor: 4.799

10.  Pharmacology of ocular drugs. 1. Timolol maleate.

Authors:  H E Kaufman
Journal:  Ophthalmology       Date:  1980-02       Impact factor: 12.079

View more
  24 in total

1.  Changes in ocular surface caused by antiglaucomatous eyedrops: prospective, randomised study for the comparison of 0.5% timolol v 0. 12% unoprostone.

Authors:  J Shimazaki; K Hanada; Y Yagi; J Yamagami; M Ishioka; S Shimmura; K Tsubota
Journal:  Br J Ophthalmol       Date:  2000-11       Impact factor: 4.638

2.  Comparison of a non-preserved 0.1% T-Gel eye gel (single dose unit) with a preserved 0.1% T-Gel eye gel (multidose) in ocular hypertension and glaucomatous patients.

Authors:  D L Easty; G Nemeth-Wasmer; J-P Vounatsos; B Girard; N Besnainou; P Pouliquen; L Delval; J-F Rouland
Journal:  Br J Ophthalmol       Date:  2006-05       Impact factor: 4.638

3.  Short-term comparative study of topical 2% carteolol with and without benzalkonium chloride in healthy volunteers.

Authors:  C Baudouin; C de Lunardo
Journal:  Br J Ophthalmol       Date:  1998-01       Impact factor: 4.638

4.  Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication.

Authors:  P J Pisella; P Pouliquen; C Baudouin
Journal:  Br J Ophthalmol       Date:  2002-04       Impact factor: 4.638

5.  Corneal toxicity secondary to inadvertent use of benzalkonium chloride preserved viscoelastic material in cataract surgery.

Authors:  H Eleftheriadis; M Cheong; S Sandeman; P P Syam; P Brittain; G K Klintworth; A Lloyd; C Liu
Journal:  Br J Ophthalmol       Date:  2002-03       Impact factor: 4.638

6.  Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients.

Authors:  Michael B Horsley; Malik Y Kahook
Journal:  Clin Ophthalmol       Date:  2009-06-02

7.  Measurement of basal tear turnover using a standardized protocol. European concerted action on ocular fluorometry.

Authors:  J A van Best; J M Benitez del Castillo; L M Coulangeon
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1995-01       Impact factor: 3.117

Review 8.  Preservative-Free Prostaglandin Analogs and Prostaglandin/Timolol Fixed Combinations in the Treatment of Glaucoma: Efficacy, Safety and Potential Advantages.

Authors:  Gábor Holló; Andreas Katsanos; Kostas G Boboridis; Murat Irkec; Anastasios G P Konstas
Journal:  Drugs       Date:  2018-01       Impact factor: 9.546

9.  [Preservatives in ophthalmology].

Authors:  E M Messmer
Journal:  Ophthalmologe       Date:  2012-11       Impact factor: 1.059

10.  German register for glaucoma patients with dry eye. I. Basic outcome with respect to dry eye.

Authors:  Carl Erb; Ulrike Gast; Dieter Schremmer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-07-22       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.